Clinical trials: Residual Disease
Cochlear Implants, Hearing Loss, Sensorineural
Clinical Trial to Compare Two Surgical Approaches to the Cochlea
This is a prospective multicenter multinational randomized control trial. The duration of the study for the individual patient will be approximately 1 year (pre-operative assessments, 1 week, 3 months and 12 months follow-up…
- Trial name
- BULLS-I (NCT06453343)
- Testing
- Surgical approach: cochleostomy or extended round window
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Deafness
Assessment of Bimodal Contribution in Adult Cochlear Implant Users
To evaluate the combination of electric hearing through Cochlear Implant and acoustic hearing through hearing aid in bimodal users with moderate-to-severe hearing loss in the non-implanted ear.
- Trial name
- NCT02331017
- Testing
- Speech perception tests and self-rating questionnaire
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Bnai Zion Medical Center
Colorectal Neoplasms
Full Thickness Resection or Endoscopic Submucosal Dissection for Difficult Colorectal Lesions.
Compare the efficacy and safety of endoscopic resection a full thickness (EFTR) with Full Thickness Resection Device (FTRD) System versus endoscopic submucosal dissection (ESD) in the treatment of Laterally Spreading Tumor Non…
- Trial name
- NCT05502276
- Testing
- Endoscopic Full-Thickness Resection (EFTR), Endoscopic Submucosal Dissection (ESD)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- University of Roma La Sapienza
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Angio-based Final Functional Effect of PCI
Fractional flow reserve (FFR) has revolutionized the diagnosis and treatment of coronary artery disease (CAD), and more recently, post percutaneous coronary intervention (post-PCI) FFR has emerged as an independent predictor of…
- Conditions
- Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Chronic Coronary Syndrome
- Trial name
- AFFE-PCI (NCT06255678)
- Testing
- Angiography-based vessel fractional flow reserve (vFFR) calculation
- Where
- Poland
- Volunteers
- 2,005 people
- Sponsor
- Medical University of Warsaw
Residual Mitral Regurgitation
Multiparametric Protocol for Assessment of Intraprocedural Result of MITRACLIP Procedure
Quantification of residual mitral regurgitation (MR) after MitraClip may be challenging. Quantitative methods for severity assessment may be inaccurate and recent recommendations suggest an assessment of changes in both…
- Trial name
- IPCLIP-2020 (NCT06184789)
- Testing
- Echocardiographic assessment
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS San Raffaele
ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I
Capecitabine in ER+/HER2-negative Breast Cancer
This is a Phase 2 study for patients with resected Stage I-III HR+/HER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo/adjuvant and locoregional therapy delivered with curative…
- Conditions
- ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT07631052
- Testing
- Capecitabine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Muscle Relaxants
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
evaluate the degree of association, and the predictive accuracy of the REPS (as a predictive tool) compared with the TOFr as a quantitative assessment tool for (rNMB) in surgical patients in the early postoperative phase.
- Trial name
- NCT06899048
- Testing
- residual neuromuscular block risk prediction score
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- Assiut University
Rectal Adenocarcinoma, Rectal Cancer
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy.
- Trial name
- NCT07292298
- Testing
- High Rare Dose Rectal Brachytherapy Boost
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Colon Adenocarcinoma, Rectal Adenocarcinoma
Evaluating Novel Therapies in ctDNA Positive GI Cancers
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- MRD-GI (NCT05482516)
- Testing
- Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Phantom Limb, Residual Limb Pain
Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation
The purpose of this study is to identify the best treatment sequence and combination of acupuncture points for the treatment of phantom limb or residual limb pain in the traumatic/surgical amputee.
- Conditions
- Phantom Limb, Residual Limb Pain, Traumatic Amputation, Amputation
- Trial name
- NCT00388752
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Walter Reed Army Medical Center
Bipolar Disorder
Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
The goals of this study are to evaluate the efficacy of JNJ-18038683 in an 8 week trial to ameliorate the cognitive deficit and reduce residual depressive symptoms in 60 stable bipolar outpatients receiving treatment for…
- Trial name
- NCT02466685
- Testing
- JNJ-18038683
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Herbert Meltzer
Chronic Lymphocytic Leukemia
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)
Phase 1: Evaluate the safety and tolerability of MEDI-538 given by escalated doses with continuous IV infusion for 4 weeks in adult patients with CLL.
- Trial name
- NCT00676871
- Testing
- MEDI-538
- Volunteers
- 30 people
- Sponsor
- MedImmune LLC
Preoperative, Gastric
Preoperative Residual Gastric Volume
The goal of this observational study is to assess the preoperative gastric residual volume in adult patients undergoing elective surgery.
- Conditions
- Preoperative, Gastric, Residual Volume
- Trial name
- NCT07031414
- Where
- Turkey (Türkiye)
- Volunteers
- 400 people
- Sponsor
- Izmir City Hospital
Non Small Cell Lung Cancer, Complete Surgical Resection
Using ctDNA to Determine Therapies for Lung Cancer
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with…
- Conditions
- Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA
- Trial name
- ctDNA Lung RCT (NCT04966663)
- Testing
- Nivolumab, Pemetrexed, Gemcitabine
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University Health Network, Toronto
Sleep, Neurobehavioral Manifestations
Hangover, Congeners, Sleep and Occupational Performance
The objective is to investigate residual effects of heavy drinking, with or without hangover symptoms. The primary aim is to test several hypotheses about residual effects of heavy drinking.
- Trial name
- NCT00247585
- Testing
- Ethanol (Bourbon or Vodka)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Leukemia, Lymphoma
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.
- Trial name
- NCT01258933
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Dental Caries
Effect of Silver Diamine Fluoride and LED Activation on Residual Caries Activity in Class II Cavities
This observational clinical study investigates the effect of silver diamine fluoride (SDF) and its activation with light-emitting diode (LED) on residual caries activity after caries excavation in Class II primary molar cavities.
- Trial name
- NCT07250009
- Testing
- DIAGNOdent measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Çanakkale Onsekiz Mart University
Plasma Cell Myeloma
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant.
- Trial name
- NCT04876248
- Testing
- Belantamab Mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma, B-Cell, Leukemia, B-Cell
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.
- Conditions
- Lymphoma, B-Cell, Leukemia, B-Cell, Minimal Disease, Residual
- Trial name
- NCT03564977
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and…
- Trial name
- NCT04419519
- Testing
- Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.